Hone Health, a physician-led virtual longevity care platform, has raised $228 million.
The investment is structured as a combination of equity and growth financing. The $28 million series A extension was led by MarcyPen Capital Partners, with participation from Pentland Ventures, Kinship Ventures, Hanwha, Gannet Capital, humbition and Comma Capital. Other angel investors also participated, including the Jonas brothers. The $200 million in growth financing came from General Catalyst’s Customer Value Fund.
Hone will use the investment to support a number of expansions. It plans to launch more programming for metabolic health, PMOS, inflammation and immunity, and to launch a physician-supervised peptide program. It will add more diagnostics, including coronary CT angiography and gut microbiome analysis.
Hone also plans to continue building out its AI operating system that brings data together to help personalize care. And, it plans to build out clinical trial infrastructure to support pharma partners.
“Longevity is thought of as this super exotic thing. … I actually think longevity is now becoming primary care,” Saad Alam, co-founder and CEO of Hone, told Fierce Healthcare.
It costs $65 to test for 70 biomarkers with Hone, followed by a clinician consult with the option to add more diagnostics. Labs, health history, symptoms and medications are run through its AI, which then gives providers treatment recommendations. Hone can keep adding additional diagnostics and medications, per Alam, “and the AI gets smarter as we get more patients into that system.”
From there, patients can become subscribers. A subscription is $150 a month, plus the cost of medications.
Source link







